Does Insurance Cover Ketamine Treatment in Florida?

Spravato is generally covered by Florida Medicaid and by most commercial plans in Florida, but almost always needs prior approval first. IV ketamine is off-label and is almost never covered by anyone. What you pay depends far more on your coverage than on which clinic you pick.

Who pays for what in Florida

Where we cannot know the answer at state level, the cell says so rather than guessing.
If you have…	Spravato typically covered?	IV ketamine?	Prior approval likely?	What your prescriber must document
Florida Medicaid	Usually, with prior approval	No	Almost always	Which antidepressants you have tried, for how long, and at what dose
Commercial (employer or marketplace)	Usually, with prior approval	No	Yes	A diagnosis, a baseline depression score, and failed antidepressant trials
Medicare (Part B)	Generally, as a clinic-administered medicine	No	Varies	Your prescriber can tell you what their billing requires
Medicare Advantage	Plan by plan — we cannot tell you	No	Usually	Ask your plan directly; network rules matter as much as criteria
VA or TRICARE	Through a referral pathway	No	Referral required	Ask your VA team; service-connected conditions typically carry no copay
Uninsured (paying cash)	You pay the clinic directly	You pay the clinic directly	Not applicable	Ask about self-pay rates and manufacturer patient assistance

Florida Medicaid is delivered through Statewide Medicaid Managed Care. Spravato does not appear on the Florida Medicaid preferred drug list at all; it is governed instead by separate published clinical criteria requiring prior approval, and by a minimum age of 18. as of 1 Jul 2026 · Florida Agency for Health Care Administration (source 3, opens in a new tab)We confirmed the absence by searching the full preferred drug list effective 1 July 2026.

Florida Medicaid approves Spravato for people aged 18 and over with treatment-resistant depression, where prior antidepressant trials of at least four weeks each did not work. Florida permits Spravato on its own for treatment-resistant depression — no companion oral antidepressant is required. Approvals are granted in three-month blocks. as of 28 Apr 2026 · Florida Agency for Health Care Administration (source 2, opens in a new tab)The state document does not name a specific number of prior antidepressants that must have failed, so we do not publish one. It also contains no REMS wording, though the federal REMS rules apply regardless.

Florida's major commercial insurers all require prior approval for Spravato, and most no longer require a companion oral antidepressant. Florida Blue covers it under the medical benefit and does not require a companion antidepressant for treatment-resistant depression. Sunshine Health is the exception: its published criteria still require one. as of 15 Apr 2026 · Florida Blue, UnitedHealthcare and Sunshine Health (source 1, opens in a new tab)Sunshine Health's document carries no revision date and its requirement predates the FDA's monotherapy approval — worth asking whether it still applies. We could not locate Humana's Florida commercial policy, so we make no claim about it.

UnitedHealthcare applies one national policy rather than a separate rule per state. It covers Spravato with prior approval for treatment-resistant depression, and requires a diagnosis made by a mental health professional, a baseline score on a recognised depression scale, failure of at least two antidepressants taken for at least eight weeks each at the highest tolerated dose, and a provider or setting certified under the Spravato REMS programme. as of 1 May 2026 · UnitedHealthcare (source 7, opens in a new tab)This is a national policy, so it reads the same wherever you live — which is why it is recorded once here rather than repeated in each state. UnitedHealthcare runs parallel medical and pharmacy versions; which one applies depends on how your clinic bills, and prior approval is needed either way.

UnitedHealthcare's national policy states that ketamine injection is investigational, and therefore not proven or medically necessary, for psychiatric conditions including depression, bipolar disorder and post-traumatic stress disorder. This is the clearest published statement of why commercial insurance rarely pays for IV ketamine. as of 1 May 2026 · UnitedHealthcare (source 7, opens in a new tab)This describes one commercial insurer. It does not describe any state Medicaid programme, none of which publishes criteria for racemic ketamine either way.

Under Original Medicare Part B in 2026 you pay a $283 yearly deductible first, and after that you generally pay 20% of the Medicare-approved amount for covered services. as of 1 Jan 2026 · Centers for Medicare and Medicaid Services (source 4, opens in a new tab)Deductible and premium amounts are set annually and change each January.

Florida Medicaid in detail

Florida Medicaid is delivered through Statewide Medicaid Managed Care. Spravato does not appear on the Florida Medicaid preferred drug list at all; it is governed instead by separate published clinical criteria requiring prior approval, and by a minimum age of 18. as of 1 Jul 2026 · Florida Agency for Health Care Administration (source 1, opens in a new tab)We confirmed the absence by searching the full preferred drug list effective 1 July 2026.

Florida Medicaid drug list and coverage information

What has to be documented before it is approved

Florida Medicaid approves Spravato for people aged 18 and over with treatment-resistant depression, where prior antidepressant trials of at least four weeks each did not work. Florida permits Spravato on its own for treatment-resistant depression — no companion oral antidepressant is required. Approvals are granted in three-month blocks. as of 28 Apr 2026 · Florida Agency for Health Care Administration (source 1, opens in a new tab)The state document does not name a specific number of prior antidepressants that must have failed, so we do not publish one. It also contains no REMS wording, though the federal REMS rules apply regardless.

In practice this documentation is what decides the outcome. If you have tried antidepressants that did not work, it is worth asking your prescriber to record which ones, at what dose, and for how long — before the request is submitted rather than after it is refused.

Commercial plans in Florida

UnitedHealthcare applies one national policy rather than a separate rule per state. It covers Spravato with prior approval for treatment-resistant depression, and requires a diagnosis made by a mental health professional, a baseline score on a recognised depression scale, failure of at least two antidepressants taken for at least eight weeks each at the highest tolerated dose, and a provider or setting certified under the Spravato REMS programme. as of 1 May 2026 · UnitedHealthcare (source 4, opens in a new tab)This is a national policy, so it reads the same wherever you live — which is why it is recorded once here rather than repeated in each state. UnitedHealthcare runs parallel medical and pharmacy versions; which one applies depends on how your clinic bills, and prior approval is needed either way.

The major insurers operating in Florida are Florida Blue, UnitedHealthcare, Sunshine Health, Humana. Criteria change, and a policy published two years ago may no longer be what your insurer applies — ask for their current criteria in writing.

The manufacturer savings programme

Through the Spravato withMe savings programme, eligible patients with commercial insurance may pay as little as $10 per treatment for the medicine itself, subject to yearly maximum benefits and quantity limits. as of 18 Jul 2026 · Johnson & Johnson (source 5, opens in a new tab)The programme covers the medicine, not the office visit or the two-hour observation, which is often the larger share of the bill. The official terms state that a yearly maximum applies but do not publish the amount, so we do not either. Terms are set per calendar year.

The Spravato withMe savings programme is not available to anyone using a state or federal government health programme, including Medicare, Medicaid, TRICARE, the Department of Defense, and the Veterans Administration. as of 18 Jul 2026 · Johnson & Johnson (source 5, opens in a new tab)

That exclusion is not a decision your plan made and not something an appeal can change. If you are on Florida Medicaid, Medicare, TRICARE or VA benefits, the copay card is not available to you, and any clinic suggesting otherwise has it wrong.

Medicare

If you have a Medigap policy it may cover most or all of that 20% share. Medicare Advantage works differently again: your plan sets its own copays and network rules, and we cannot usefully estimate those — your plan's member services line can.

What the FDA label and typical payer criteria say

Insurers generally look for a diagnosis of treatment-resistant depression, meaning depression that has not responded adequately to at least two antidepressants taken at a proper dose for a proper length of time. Most also want a baseline score on a recognised depression scale, and involvement from a psychiatrist.

On 17 January 2025 the FDA approved Spravato for treatment-resistant depression in adults either on its own or together with an oral antidepressant, so a companion oral antidepressant is now optional for this use — though it is still permitted. as of 17 Jan 2025 · U.S. Food and Drug Administration (source 5, opens in a new tab)This applies to the treatment-resistant depression indication only. The separate indication for major depressive disorder with acute suicidal ideation still requires an oral antidepressant — see spravato.approval_mdd_si. Widely-cited secondary sources give 21 January 2025; that is the manufacturer's announcement date, not the FDA action date on the approval letter.

On 31 July 2020 the FDA separately approved Spravato, used together with an oral antidepressant, for depressive symptoms in adults who have major depressive disorder with acute suicidal thoughts or behaviour; for this use the oral antidepressant is still required, and it is not a substitute for hospital care when hospital care is needed. as of 31 Jul 2020 · U.S. Food and Drug Administration (source 5, opens in a new tab)

None of this tells you whether you personally qualify. That is a judgement for a clinician who knows your history, working with your insurer. What it does tell you is what the conversation will be about, and what to bring to it.

If you are turned down

A refusal is not the end of the process. In order, the things that actually change outcomes:

Ask for the specific reason in writing. "Not medically necessary" is not a reason; the criterion you failed to meet is.
Ask your prescriber for a peer-to-peer review. This is a direct conversation between your prescriber and a clinician at the insurer, and it resolves a meaningful share of refusals — usually because the original request was missing documentation rather than because you did not qualify.
Fill the documentation gap. Most refusals turn on trial length, dose, or a missing baseline score. Those are fixable.
Request an external review. If the internal appeal fails, you can ask for an independent review outside the insurer. Your state insurance regulator can tell you how, and the deadline for asking is usually short — check it the day you receive the refusal.

If you have no insurance

Ask clinics directly whether they have a self-pay rate — it is often lower than the price they bill insurers. Ask the manufacturer about patient assistance, which is separate from the copay card and does reach some uninsured patients. And use our question checklist so the number you are quoted is a complete one rather than a starting point.